SMTI (Sanara MedTech) Other Long-Term Liabilities: $0.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMTI Sanara MedTech Inc SMTI
81 GF Score
Price $35.12
GF Value $44.24
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sanara MedTech Other Long-Term Liabilities?

Sanara MedTech SMTI +0.06% 81 Other Long-Term Liabilities is $0.6 Mil as of Jun. 2026. GuruFocus rates SMTI with a GF Score™ of 81/100 and a GF Value™ of $44.24 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sanara MedTech's other long-term liabilities for the quarter that ended in Jun. 2026 was $0.6 Mil.

Sanara MedTech's quarterly other long-term liabilities increased from Dec. 2025 ($0.5 Mil) to Mar. 2026 ($0.6 Mil) and increased from Mar. 2026 ($0.6 Mil) to Jun. 2026 ($0.6 Mil).

Sanara MedTech's annual other long-term liabilities declined from Dec. 2023 ($4.7 Mil) to Dec. 2024 ($2.0 Mil) and declined from Dec. 2024 ($2.0 Mil) to Dec. 2025 ($0.5 Mil).

Sanara MedTech Other Long-Term Liabilities Related Terms

Sanara MedTech Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sanara MedTech's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech Other Long-Term Liabilities Chart

Sanara MedTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 6.00 4.66 1.96 0.55

Sanara MedTech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 0.54 0.55 0.56 0.57
SMTI
81GF Score
Sanara MedTech Inc SMTI
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanara MedTech Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.6 Mil mean?
Sanara MedTech (SMTI) has a Other Long-Term Liabilities of $0.6 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sanara MedTech and its competitors.
Is Sanara MedTech's Other Long-Term Liabilities too high?
Sanara MedTech's current Other Long-Term Liabilities is $0.6 Mil. Overall, Sanara MedTech has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Other Long-Term Liabilities compare to NNNN and EMBC?
Sanara MedTech's Other Long-Term Liabilities of $0.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sanara MedTech and its competitors. Sanara MedTech's current Other Long-Term Liabilities is $0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $44.24, compared to a current price of $35.12 — trading 20.6% below its estimated fair value. The current Other Long-Term Liabilities is $0.6 Mil. Sanara MedTech's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Other Long-Term Liabilities is $0.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $35.12 is trading 20.6% below its estimated GF Value™ of $44.24. GuruFocus considers Sanara MedTech to be Modestly Undervalued.

Key valuation signals for SMTI:

  • Other Long-Term Liabilities: $0.6 Mil
  • GF Value™: $44.24 vs. price of $35.12 (20.6% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
81GF Score

Get the complete analysis for SMTI

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.12
Price
$44.24
GF Value